STATE OF MICHIGAN MICHIGAN ADMINISTRATIVE HEARING SYSTEM FOR THE DEPARTMENT OF COMMUNITY HEALTH

P.O. Box 30763, Lansing, MI 48909 (877) 833-0870; Fax: (517) 373-4147

IN THE MATTER OF:	Dealest No.	44 04C20C DUD
	Docket No.	14-016386 PHR
Appellant /		
DECISION AND	ORDER	
This matter is before the undersigned Administrated and 42 CFR 431.200 et seq., following Appellant		
After due notice, a hearing was held on testified. Appellant's mother, leading also appears also appears to the Respondent, Michigan Depart Respondent).	peared and testified	pellant appeared and d on Appellant's behalf. (MMA), nity Health (MDCH or
ISSUE		
Did the Department properly deny the Appella Suboxone?	ant's request for	prior authorization of
FINDINGS OF FACT		

Appellant is a Medicaid beneficiary.

on the whole record, finds as material fact:

1.

2. On Appellant sought prior authorization for treatment with Suboxone.

The Administrative Law Judge based on the competent, material, and substantial evidence

- 3. Appellant's claim history shows that Appellant had previously had Suboxone prescriptions three times from .
- 4. The request from Appellant's physician was for a restart of medication for months of therapy, Respondent's Exhibit 1.
- There was no reason given for the lapse in the previous therapy by Appellant's treating physician for the prescription for re-start of Suboxone in the prior authorization request.

- 6. An Adequate Action Notice of denial was sent to the Appellant on

CONCLUSIONS OF LAW

The Medical Assistance Program is established pursuant to Title XIX of the Social Security Act and is implemented by Title 42 of the Code of Federal Regulations (CFR). It is administered in accordance with state statute, the Social Welfare Act, the Administrative Code, and the State Plan under Title XIX of the Social Security Act Medical Assistance Program.

The Social Security Act § 1927(d), 42 USC 1396r-8(d), provides as follows:

LIMITATIONS ON COVERAGE OF DRUGS -

- (1) PERMISSIBLE RESTRICTIONS -
 - (A) A state may subject to prior authorization any covered outpatient drug. Any such prior authorization program shall comply with the requirements of paragraph (5).
 A state may exclude or otherwise restrict coverage of a covered outpatient drug if –
 - the prescribed use is not for a medically accepted indication (as defined in subsection (k)(6);
 - (ii) the drug is contained in the list referred to in paragraph (2);
 - (iii) the drug is subject to such restriction pursuant to an agreement between a manufacturer and a State authorized by the Secretary under subsection (a)(1) or in effect pursuant to subsection (a)(4); or
 - (iv) the State has excluded coverage of the drug from its formulary in accordance with paragraph 4.
- (2) LIST OF DRUGS SUBJECT TO RESTRICTION The following drugs or classes of drugs, or their medical uses, may be excluded from coverage or otherwise restricted:
 - (A) Agents when used for anorexia, weight loss, or weight gain.
 - (B) Agents when used to promote fertility.

- (C) Agents when used for cosmetic purposes or hair growth.
- (D) Agents when used for the symptomatic relief of cough and colds.
- (E) Agents when used to promote smoking cessation.
- (F) Prescription vitamins and mineral products, except prenatal vitamins and fluoride preparations.
- (G) Nonprescription drugs.
- (H) Covered outpatient drugs, which the manufacturer seeks to require as a condition of sale that associated tests or monitoring services be purchased exclusively from the manufacturer or its designee.
- (I) Barbiturates.
- (J) Benzodiazepines.
- (K) Agents when used for the treatment of sexual or erectile dysfunction, unless such agents are used to treat a condition, other than sexual or erectile dysfunction, for which the agents have been approved by the Food and Drug Administration.

* * *

- (4) REQUIREMENTS FOR FORMULARIES A State may establish a formulary if the formulary meets the following requirements:
 - (A) The formulary is developed by a committee consisting of physicians, pharmacists, and other appropriate individuals appointed by the Governor of the State (or, at the option of the State, the State's drug use review board established under subsection (g)(3)).
 - (B) Except as provided in subparagraph (C), the formulary includes the covered outpatient drugs of any manufacturer, which has entered into and complies with an agreement under subsection (a) (other than any drug excluded from coverage or otherwise restricted under paragraph (2)).

- (C) A covered outpatient drug may be excluded with respect to the treatment of a specific disease or condition for an identified population (if any) only if, based on the drug's labeling (or, in the case of a drug the prescribed use of which is not approved under the Federal Food, Drug, and Cosmetic Act but is a medically accepted indication, based on information from appropriate compendia described in subsection (k)(6)), the excluded drug does not have a significant, clinically meaningful therapeutic advantage in terms of safety, effectiveness, or clinical outcome of such treatment for such population over other drugs included in the formulary and there is a written explanation (available to the public) of the basis for the exclusion.
- (D) The state plan permits coverage of a drug excluded from the formulary (other than any drug excluded from coverage or otherwise restricted under paragraph (2)) pursuant to a prior authorization program that is consistent with paragraph (5).
- (E) The formulary meets such other requirements as the Secretary may impose in order to achieve program savings consistent with protecting the health of program beneficiaries.

A prior authorization program established by a State under paragraph (5) is not a formulary subject to the requirements of this paragraph.

- (5) REQUIREMENTS OF PRIOR AUTHORIZATION PROGRAMS — A State plan under this title may require, as a condition of coverage or payment for a covered outpatient drug for which Federal financial participation is available in accordance with this section, with respect to drugs dispensed on or after July 1, 1991, the approval of the drug before its dispensing for any medically accepted indication (as defined in subsection (k)(6)) only if the system providing for such approval —
 - (A) Provides response by telephone or other telecommunication device within 24 hours of a request for prior authorization; and
 - (B) Except with respect to the drugs referred to in paragraph (2) provides for the dispensing of at least 72hour supply of a covered outpatient prescription drug in an emergency situation (as defined by the Secretary).

Docket No. 14-016386 PHR Decision and Order

42 USC 1396r-8(k)(6) MEDICALLY ACCEPTED INDICATION -

The term "medically accepted indication" means any use for a covered outpatient drug which is approved under the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 301 et seq.] or the use of which is supported by one or more citations included or approved for inclusion in any of the compendia described in subsection (g)(1)(B)(i).

The Medicaid Provider Manual addresses prior-authorization requirements as follows:

8.2 PRIOR AUTHORIZATION REQUIREMENTS

PA is required for:

- Products as specified in the MPPL. Pharmacies should review the information in the Remarks as certain drugs may have PA only for selected age groups, gender, etc. (e.g., over 17 years).
- Payment above the Maximum Allowable Cost (MAC) rate.
- Prescriptions that exceed MDCH quantity or dosage limits.
- Medical exception for drugs not listed in the MPPL.
- Medical exception for noncovered drug categories.
- Acute dosage prescriptions beyond MDCH coverage limits for H2 Antagonists and Proton Pump Inhibitor medications.
- Dispensing a 100-day supply of maintenance medications that are beneficiary-specific and not on the maintenance list.
- Pharmaceutical products included in selected therapeutic classes. These classes include those with products that have minimal clinical differences, the same or similar therapeutic actions, the same or similar outcomes, or have multiple effective generics available.

* * *

8.4 DOCUMENTATION REQUIREMENTS

For all requests for PA, the following documentation is required:

- Pharmacy name and phone number;
- Beneficiary diagnosis and medical reason(s) why another covered drug cannot be used;
- Drug name, strength, and form;
- Other pharmaceutical products prescribed;
- Results of therapeutic alternative medications tried; and
- MedWatch Form or other clinical information may be required.

* * *

8.6 PRIOR AUTHORIZATION DENIALS

PA denials are conveyed to the requester. PA is denied if:

- The medical necessity is not established.
- Alternative medications are not ruled out.
- Evidence-based research and compendia do not support it.
- It is contraindicated, inappropriate standard of care.
- It does not fall within MDCH clinical review criteria.
- Documentation required was not provided.

MDCH Medicaid Provider Manual; Pharmacy Section Version Date: October 1, 2013, pp 13-15

The Respondent's representative testified that the Appellant's treating physician must submit the request for a renewal request. The Michigan Medicaid Clinical and PDL Criteria indicate that renewal requests for interrupted/restart therapy requires an MDCH review. All of the following are required for an MDCH review/approval:

- The information requested for the initial approval.
- Some reference to the reason(s) for the lapse in therapy.
- A screen print of paid claims through POS claims history.

Docket No. 14-016386 PHR Decision and Order

In the instant case, the treating physician did not provide reference to the reason(s) for the
lapse in therapy. The request was forwarded to MDCH, Physician Reviewer, who concurred
in denial of the coverage based upon insufficient information and a request that
the treating physician submit an explanation as to why the lapse in treatment occurred and
how this is being addressed by the provider in the plan of care.

Appellant testified that she went to jail until until until . She did not take the Suboxone while she was incarcerated. Upon being released from jail she returned to her heroin use, and continued to use heroin until . She was not taking Suboxone from through . She started Suboxone treatment in and has been paying out of pocket for her treatment. She has requested that her treating physician provide the requested information to so that Medicaid will cover her Suboxone prescription. She is currently compliant with her medical regimen and provided letters from her current medical providers in support of that allegation.

This Administrative Law Judge finds that under the circumstances presented at hearing, Appellant did not meet the Medicaid standards of coverage and documentation requirements to establish medical necessity for the requested Suboxone because the treating physician did not provide some reference to the reason(s) for the lapse in the previous therapy in the prior authorization request. Accordingly, the Department's denial is proper based on the submitted information.

DECISION AND ORDER

The Administrative Law Judge, based on the above findings of fact and conclusions of law, must find that the Department was within its legal authority to deny coverage for the medication sought.

IT IS THEREFORE ORDERED that:

The Department's decision is AFFIRMED.

Landis Y. Lain
Administrative Law Judge
for Nick Lyon, Director
Michigan Department of Community Health

Date Signed:	
_	
Date Mailed:	

Docket No. 14-016386 PHR Decision and Order

LYL/db

CC:



*** NOTICE ***

The Michigan Administrative Hearing System for the Department of Community Health may order a rehearing on either its own motion or at the request of a party within 30 days of the mailing date of this Decision and Order. The Michigan Administrative Hearing System for the Department of Community Health will not order a rehearing on the Department's motion where the final decision or rehearing cannot be implemented within 90 days of the filing of the original request. The Appellant may appeal the Decision and Order to Circuit Court within 30 days of the receipt of the Decision and Order or, if a timely request for rehearing was made, within 30 days of the receipt of the rehearing decision.